• Muhammad Aamir Waheed, Khalid Rashid, Tawfik Rajab, Ahmad Rajab, Adnan H Adnan, Harris Fayyaz, Ahmad A Ibad, Rabia Basri, Yahya Khan, Habib I Alhabib, and Abdelnaser Elzouki.
• From the Department of Acute Medicine (Waheed, Rajab, Adnan, Fayyaz) University Hospitals Northampton, Northampton; from the Department of Cardioloogy (Rashid), James Cook University Hospital, Middlesbrough; from the Department of Internal Medicine (Rajab), Calderdale and Huddersfield NHS Foundation Trust, England, United Kingdom; from the Department of Pathology (Ibad), Bannu Medical College, Khyber Medical University, Bannu; from the Department of Medical Education (Khan), Pak International Medical College, Peshawar, Pakistan; from the Department of Anesthesia (Basri), Hamad Medical Corporation; from the Department of Internal Medicine (Elazouki), Hamad Medical Corporation and Weill Cornell Medical College of Qatar, Doha, Qatar; from the Department of Internal Medicine (Alhabib), Dr. Mahasen's Medical Complex, Al Qassim, Kingdom of Saudi Arabia.
• Saudi Med J. 2022 Jun 1; 43 (6): 541-550.

ObjectivesTo reducing the risk of venous thromboembolic (VTE) events and subsequent mortality in covid-19 patients is still a matter of research. This systematic review and meta-analysis serve the purpose of comparing the mortality associated with the intensity of anticoagulation in patients admitted with covid-19.MethodsA total of 7120 patients were recruited in 11 studies comparing using prophylactic anticoagulants against therapeutic anticoagulants.ResultsOur study showed that using prophylactic anticoagulants was associated with a 42% reduction in mortality compared to therapeutic anticoagulants (OR 0.58 (95% CI:0.676-0.499), p=0.000). Also, we assessed mortality in patients using no anticoagulants against using prophylactic anticoagulants. A total of 6069 patients were recruited in 4 studies in which 2 studies significantly favored prophylactic anticoagulants in terms of reducing mortality. Cumulatively, the meta-analysis showed that using prophylactic anticoagulants was associated with a 5% reduction in mortality but without any statistical significance: (OR 1.049 [95% CI 1.237 - 0.865]) (p=0.626).ConclusionOur meta-analysis favors using prophylactic anticoagulation in covid-19 patients reduces all-cause mortality in comparison to therapeutic anticoagulation however the impact on mortality when compared with no anticoagulation was not significant.PROSPERO Number: CRD42021257320.Copyright: © Saudi Medical Journal.

16 keywords...

hide…